Abstract
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) commonly used on the treatment of Acquired Immunodeficiency Syndrome (AIDS) due its potent antiviral activity and clinical effectiveness when combined with two nucleoside reverse transcriptase inhibitors (NRTI) in the first line antiretroviral therapy (ART). Efavirenz is classified as class II in the Biopharmaceutics Cl…